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Introduction
Despite the systemic manifestation and early onset of many inherited diseases, most present efforts towards somatic gene therapy concentrate on the treatment of adult patients. By applying gene therapy vectors at mid to late pregnancy into the amniotic cavity, the fetal circulation, or by topical application to selected organ systems it may be possible to begin treatment sufficiently early to prevent the development of any tissue damage and enable prevention rather than treatment of the disease. During fetal development still expanding stem cell populations and organ or cell systems which are difficult to access later in life may be targetable thus providing a basis for permanent somatic gene correction. In utero gene delivery may also give the opportunity to avoid immune-sensitisation and thereby, as an alternative, facilitate repeated treatment after birth. 1, 2 Several groups have attempted gene delivery to the respiratory system by instillation of adenoviral or retroviral vectors into the airways and the amniotic cavity of fetal sheep. [3] [4] [5] [6] Delivery into the amniotic cavity of rats and mice has been used to target the fetal airways and the intestine. [6] [7] [8] [9] Among rodents, the mouse is a very convenient animal model for approaches to prenatal gene therapy because of the ease of breeding and the existence of many mouse models of human genetic diseases. In rabbits, systemic application by fetal heart puncture has been used for gene delivery to the liver 10 which is a very important target for gene therapy of many inborn errors of metabolism, as well as of deficiencies in blood clotting factors. However, the small size of rodents imposes severe restrictions to investigations on vector delivery with relevance to future applications in humans and on studies relating to the long-term effects of the different vector systems. As an alternative, due to their size sheep provide a model to examine vector applications which are relevant to the human situation and allow more accurate studies of gene delivery and long-term expression. In particular ultrasound-guided needling of the umbilical vein is a well established procedure for diagnostic and therapeutic purposes during human pregnancy.
In this article we show effective expression of ␤-galactosidase and human factor IX transgenes in fetal sheep following administration of adenoviral vectors through the umbilical vein in late pregnancy. This route of administration targets predominantly the liver, but due to fetal shunting mechanisms, other organ systems in the large circulation are infected; in particular the adrenal cortex but also the fetal gonads. We demonstrate the presence of transgenic RNA in most infected organs with the exception of the placenta and gonads. ␤-Galactosidase protein was detected predominantly in the liver and in the adrenal cortex of fetuses and lambs. High levels of factor IX were found in the plasma of healthy lambs for several days after delivery.
Results
Choice of vector, transgene and delivery route The aim of this study was to investigate the possibility of adenovirus-mediated gene delivery to the liver and the possible spread to other organ systems of the fetus or the mother after vector application via the umbilical vein, and to study expression of the introduced transgenes in utero and after birth. With this in mind we have chosen adenovirus, as the presently most effective gene transfer system, to deliver two complementary transgenic proteins. One, ␤-galactosidase, allows tracing of the pattern of adenoviral infection at a set time point by histochemical analysis. The other, factor IX, which is also a potential therapeutic gene product, can be detected without the need to kill the animal, and thus enables repeated analysis of the transgenic protein over a longer period of time.
Since the tolerance dose of adenovirus in fetal sheep was unknown to us we chose to apply a dose range of adenovirus between 10 11 to 2.4 × 10 12 p.f.u. using AdRSV␤gal (encoding the ␤-galactosidase gene) and AdTG9397 (encoding the human factor IX gene) ( Table  1) . We assume that the dose of the adenovirus rather than the specific transgene accounts for toxic reactions. We found that a dose up to 4.8 × 10 11 p.f.u. (low dose) was still tolerated at intra-umbilical injection, while doses of 2.4 × 10 12 p.f.u. (high dose) of ␤-galactosidase or factor IXadenovirus, respectively, led to intrauterine death.
To apply the vector systems, the umbilical vein was accessed under general anaesthesia by ultrasound-guided puncture (Figure 1 ) through the exposed uterine wall or by percutaneous application ( Table 1) . One of the lowdose AdRSV␤gal-treated animals was found dead at the scheduled post mortem-examination after 3 days. The death of this animal is, however, most likely due to operation-related stress, which included laparotomy of the mother, rather than to virus toxicity (Table 1) .
Post-mortem analysis
No macroscopic abnormalities were detected in any of the maternal sheep post mortem. The post-mortem analysis of the high dose-treated fetuses (Nos 3 and 6) showed severely swollen and haemorrhagic livers with rupture of the capsule in one fetus. The lung of the latter fetus displayed focal petechial haemorrhage. The adrenal cortex appeared thin which is consistent with antemortal stress. Histologically, the livers showed marked sinusoidal congestion. A diffuse infiltration by lymphocytelike cells was found in the fetus which was treated with the high-dose factor IX vector (No. 6). This was, however, not seen in the fetus which received the AdRSV␤gal vector (No. 3). Areas of interstitial haemorrhage were found in the lung. No thrombosis was seen.
Fetus No. 4 which received a low dose of the ␤-gal virus and was killed after 3 days showed a yellow cut of the liver but no other macroscopic abnormality. Histologically, the liver revealed intra-hepatic cholestasis without inflammation. No histological changes were seen in the other organs. The low dose-treated fetus (No. 1) which died most likely due to operation-related stess in utero displayed autolytic changes. Both the low-dose factor IX-treated fetus (No. 8) and its non-treated twin (No. 9) which were killed on day 3 showed abnormal livers by histology. There were multiple granulomas with central fibrinoid necrosis or central microabscess formation. The appearances suggested infection unrelated to our intervention, possibly with Listeria, although samples were not available for microbiological analysis.
Four lambs were born completely healthy and developed well until death (Nos 5 and 7) or during longer observation (Nos 10 and 11). Post-mortem all organs appeared macroscopically normal except for a very mild focal acute bronchopneumonia but no other histological abnormality in lamb No. 5.
Intra-umbilical delivery results in widespread distribution and transcription of the adenoviral vector
To investigate the efficiency of infection with the adenovirus vector and its DNA transcription in different tissues we applied PCR and RT-PCR as highly sensitive methods. Positive PCR results will indicate how far the vector travelled in the general circulation after application through the umbilical vein. We initially analysed the PCR products generated by 35 cycles of first round PCR on a range of tissues from two animals (Nos 4 and 5) which were injected with the AdRSV␤gal vector and on the maternal liver, lung and gonads of both fetuses ( Table 2) . We found strong signals on the samples from the liver of the animal killed after 3 days (No. 4) and weak signals on samples from its lung, gonads, adrenals and kidneys. Strong signals were also obtained from the liver tissue of the animal which was killed 1 day after birth (No. 5) and weak or no signals on all other tissues ( Table 2) . We then subjected all samples to a nested PCR reaction. Figure 2 shows the gel electrophoresis of the nested PCR products. Samples from a non-injected fetus (No. 2) and a fetus which was injected with the factor IX virus (No. 6) were used as negative controls throughout. Virtually all fetal and neonatal tissues of both, injected fetuses, and the maternal liver of fetus No. 4 (but not of fetus No. 5) show the presence of the expected 508 bp nested PCR band indicating broad haematogenic spread of the adenoviral vector throughout the animal and transplacental passage to the maternal circulation. No PCR product was detected in the control samples.
Transcription of the virus was investigated by RT-PCR ( Figure 3 ) and showed positive results (192 bp band) in all fetal tissues in which the adenovirus vector was detected by PCR except for the placenta and gonads, which were analysed repeatedly to confirm this exception ( Table 2 ). Lack of detection does not, however rule out low level expression in these tissues. 
Selective production of transgenic protein in different tissues and cells
To investigate the distribution of transgenic protein synthesis in the different tissues infected with the AdRSV␤gal vector we collected samples from almost all organs of the fetuses and from three maternal organs and analysed them for the presence (by immuno-staining) and activity of the recombinant ␤-galactosidase. Those showing positive results in fetuses 4 and 5 are summarised in Table 2 . In spite of the widespread vector distribution and transcription we observed a quite remarkable selectivity in the distribution of transgenic protein synthesis between organs and with respect to the different cell types in infected organs. The most intensive and widely distributed staining for ␤-galactosidase was found in fetus No. 4, which was killed 3 days after AdRSV␤gal adenovirus injection (Table 2) . Widespread immuno-histochemical nuclear staining for ␤-galactosidase was seen in the liver (Figure 4a, b) where staining was present in samples from all areas including the portal region and both lobes. ␤-Galactosidase gene expression appeared to be almost exclusively localised in hepatocytes with up to 30% staining in the areas with strongest staining. Staining was present in all zones of the acinus with no preferential localisation. In addition to hepatocytes, ␤-galactosidase staining was also detected occasionally in endothelial cells lining central veins and in cells with elongated nuclei which may represent Kupffer cells. No staining was seen in bile ducts or other portal tract structures, or in haematopoietic cells.
The adrenal gland showed prominent localisation of transgenic ␤-galactosidase in cortical cells with very occasional cells stained in the medulla (Figure 4c ). In the lung, rare positive cells were seen in alveolar walls but no staining was present in the airways. Occasionally cells with positive staining were found in the heart; the morphology suggested that these were myocytes. In particular no staining by either method was detected in the testes (Figure 4d) . No immuno-histochemical staining for ␤-galactosidase was found in the placenta. Sections of maternal lung, liver and ovary were examined and did not show any staining.
In the fetus which was found dead at post-mortem examination (No. 1) we observed some ␤-galactosidase staining in both lobes of the liver but in no other organ and the percentage of stained liver cells was less than in the fetus which survived 3 days (No. 4) .
The fetus which died shortly after vector administration (No. 3) showed, as expected, no staining. The lamb which was killed 1 day after birth (9 days after vector administration, No. 5) displayed ␤-galactosidase immuno-staining in about 1% of hepatocytes, but no staining was seen in the adrenals, lung, kidneys or gonads in spite of positive PCR and RT-PCR (except for gonads).
Immuno-histochemistry on the tissues of the fetus which received the high-dose factor IX adenovirus and died within 24 h (No. 6) showed widespread and intensive granular staining of many hepatocytes ( Figure 5 ). No staining was observed in the mother. In the fetus killed 3 days after factor IX adenovirus administration there were scattered groups of hepatocytes with positive immunohistochemical staining (No. 8). No staining was observed in the abundant haematopoietic cells present in the liver of these fetuses. No staining with the anti-factor IX antibody was seen in any of the fetuses treated with AdRSV␤gal as was no ␤-galactosidase staining observed in the fetuses which received factor IX adenovirus. In the high dose factor IX adenovirus-treated fetus we did, however, detect significant factor IX staining of airway epithelia, of adrenal cortex cells and of the endothelial and interstitial cells in the testes, but not in the tubular cells of this organ. Alerted by this widespread distribution which contravenes the results of ␤-galactosidase expression in the fetuses treated with AdRSV␤gal we probed normal human testes with the anti-factor IX antibody and found interstitial staining. This indicates that the positive reaction in this organ is due to uptake of factor IX from the blood stream rather than genuine transgene expression. However the intensive granular staining of the fetal sheep liver is most likely the result of transgenic bioproduction of factor IX.
Plasma concentrations of human factor IX reach therapeutic levels after intra-umbilical vector delivery Human factor IX levels in the plasma of two fetuses which had received the high (No. 6) or low dose (No. 8) of the factor IX adenovirus, and of three newborn lambs after low-dose adenovirus administration (Nos 7, 10, 11) were used to investigate the kinetics of transgenic protein production. Plasma concentrations of factor IX reached 404 ng/ml at death of the fetus No. 8 on the third day after gene delivery which is supposed to give the maximum value of adenovirus-mediated transgene expression. This relatively low level may be due to the 
Figure 5 Immunohistochemistry for human factor IX on liver from the fetus transfected with high dose factor IX adenovirus (No. 6). Granular staining is present in the cytoplasm of many hepatocytes. Note the prominent lymphocytic inflammatory infiltrate. Final magnification × 200.
unrelated liver infection observed in this fetus. In contrast, the lamb born 8 days after virus administration (No. 10) had a plasma concentration of 3227 ng/ml transgenic factor IX at birth and remained at high levels until the end of the study (1 week after birth). In another lamb, born 7 days after virus application (No. 7), human factor IX was found only at a concentration of 89 ng/ml at birth and fell over 7 days to 10 ng/ml at death. A third lamb (No. 11) born 15 days after gene delivery still had a plasma concentration of 129 ng/ml at birth ( Figure 6 ). Factor IX became also detectable at very low levels in the circulation of one of the mothers (of lamb No. 7) 24 h after administration of the virus. Several factors will play a role in determining the kinetics of the factor IX level. Usually the maximum of adenoviral expression is reached after 48 to 72 h. Vector elimination and promoter shutdown, the half-life of the protein and immune reactions will contribute to the consecutive fall in the plasma levels. To investigate the immune response to the vector and/or the transgenic protein we analysed sera from the treated fetuses/lambs for the presence of anti-adenoviral and anti-human factor IX antibodies before treatment and at several time points after gene transfer. No antibodies against vector or transgenic protein could be detected in pre-immune fetal sera. In the lamb that showed low levels of factor IX at birth followed by further decline (No. 7), anti-adenoviral antibodies were found already on day 8. This lamb also developed a small rise of anti-human factor IX antibodies following gene delivery. In the lamb showing continuous high-level expression of factor IX until day 12 (No. 10) both anti-adenoviral and anti-human factor IX antibodies became detectable at very low levels on day 10 and had by day 12 not yet reached the levels observed in the other lamb (No. 7) already on day 8.
Discussion
The molecular basis of most inborn errors of metabolism are mutations in genes which are expressed in liver cells. Among these diseases are phenylketonurea and other defects in amino-acid pathways, urea cycle defects such as the ornithine transcarbamylase deficiency, the alpha-1-antitrypsin deficiency, dysfunctions in the carbohydrate metabolism, storage diseases, and deficiencies of serum proteins including apo(lipo)proteins and the clotting factors. All such diseases need lifelong treatment, often with limited degrees of success. We have, therefore, in this study investigated the liver as an important target organ for fetal gene therapy.
Although sheep are expensive, have a restricted breeding season and a relatively long gestation time, which all make it difficult to generate statistically validated data, we have chosen this model to develop a technology which could be applicable, in the future, to humans. We show here by molecular and histochemical analysis that the liver can be relatively easily accessed for gene delivery using ultrasound-guided application into the umbilical vein. Initially these experiments were performed on the exposed uterus after laparotomy. However, after refinement we were able to apply vectors to the fetal sheep by ultrasound-guided percutaneous puncture of the umbilical vein. This procedure is used in human pregnancy with a risk of fetal loss of less than 1%. 11 About 50% of the placental blood flows into the liver and from there to the vena cava inferior and is distributed either to the right atrium or, through the foramen ovale, to the left atrium. The remaining 50% bypass the liver through the ductus venosus to reach the heart directly. The high rate of liver infection found in this study is therefore not surprising. However, even in this organ cell selectivity is observed as hepatocytes are preferentially targeted by the adenoviral vector. Since the lung circulation is, to a large extent, short circuited by the foramen ovale in the atria and the ductus arteriosus, it could also be expected that very little or no transgene expression is observed in this organ.
That most other organ systems did not show significant transgene expression on the protein level compared with the liver is most likely due to virus dilution in the circulation which is also demonstrated by the differences between organs in the first round PCR. However, the PCR results also indicate that a substantial amount of the vector reaches the general circulation and that it is at least transcribed in most organs where it is detected. An unexpected finding of this study is the high and preferential transgene expression in the adrenal cortex. It is well known that the adrenal blood flow in the fetal sheep may increase to 200-300%
12 during stress and this may well contribute to a high exposure of this organ to the vector. In addition, a so far unknown tropism of the adenovirus for the adrenal cortex seems to exist and could perhaps be exploited for gene therapy of disorders of this endocrine gland such as congenital adrenal hypoplasia. That this organ which is situated far downstream from the site of administration was efficiently infected indicates the great potential of this route of administration provided suitably targeted vectors for specific organ/cell systems are used.
However, this widespread delivery of the vector also poses the question of inadvertent gene delivery to unwanted sites, including germ cells and maternal tissues. In most tissues this will depend on the applied transgene and its physiological effect if expressed. The possibility of an inadvertent gene transfer into germ cells has recently caused much controversy and debate. 13, 14 Since adenovirus is not an integrating vector there is no real danger of germline transmission in these experiments. We also did not observe expression of the ␤-galactosidase transgene, either by immuno-detection or by repeated RT-PCR analysis. Widespread detection of retroviral vector sequences in many tissues including the reproductive organs of sheep born after intraperitoneal vector injection in utero and in maternal tissues was recently reported by Porada et al. 15 However, no indication for the presence of vector sequences was found by PCR analysis of purified sperm from the prenatally infected rams in this study and no vector sequences were detected in a range of investigated tissues from the offspring of the in utero-treated animals.
Factor IX is the protein which is missing or non-functional in haemophilia B (factor IX deficiency, Christmas disease). This X-linked recessively inherited disease with 1246 an incidence of about 1:25 000 males requires lifelong supplementation of the missing factor IX which plays an important role in the blood clotting cascade. As this is not only expensive but also a constant and serious burden for the patients, an alternative therapy is desirable. The normal concentration of factor IX in the human plasma is 4000 ng/ml; patients with less than 1% of this level are severely affected. Current treatment aims to maintain the factor IX level above 4% of normal to alleviate the spontaneous bleeding, which can be life-threatening or lead to chronic disabilities. Several in vivo gene therapy studies for this disease have targeted the liver with different vectors systems [16] [17] [18] [19] [20] [21] [22] and in most studies therapeutic plasma concentrations of factor IX could be achieved. The peak plasma levels of human factor IX measured in this study, representing a range of 10 to 80% of the normal human factor IX concentration, are in good agreement with these investigations.
The high rate of infection of hepatocytes detected by ␤-galactosidase histochemistry and the concentrations of factor IX in the fetal circulation which are well within the therapeutic range demonstrate the proof of principle that gene administration into the umbilical vein can provide levels of gene transfer which offer a therapeutic perspective. The decrease of the factor IX levels and the parallel increase of antibodies against adenovirus are well known problems with first generation adenoviral vectors, which were used in this study because of their high gene transfer efficiency. Obviously the gestational age chosen for these investigations is not early enough to achieve immune tolerance, which would also have allowed repeated application after birth. Approaches to achieve longer lasting and repeated gene expression could include the application at pre-immune stages of pregnancy 15 and/or the use of less immunogenic vectors such as the new generation of 'gutless' adenoviral vectors, 23 or of non-viral vector systems. [24] [25] [26] Alternatively, and probably even more suitable, the fetal organs may contain a sufficient number of dividing cells with stem cell character to achieve permanent transduction by retroviral/lentiviral 27, 28 or adeno-associated virus vectors. 21, 22, 29 A related problem which may be overcome with the future refinement of the vector systems is the acute doserelated toxicity seen in our investigations. Given that these problems can be solved and that safe and reliable technologies are developed, fetal gene therapy may also become applicable to the short-term management of some perinatal conditions such as surfactant deficiency.
Although many questions still remain to be answered before in utero gene delivery can be attempted for the treatment of human genetic disease we believe that the successful and widespread gene delivery to the liver and adrenal gland demonstrated here have brought this goal one step closer.
Materials and methods

Animals and procedures
Eleven fetuses between 102 and 140 days of gestation (term 147) from nine ewes of Romney (five) and Charolais (four) breed were used in these experiments. Only one of each twins in two twin pregnancies was given the viral vector while the other one was used as a control (Table 1) The sheep were given general anaesthesia (thiopentone 1 g i.v. for induction, then halothane 2% in O 2 for maintenance). Ultrasound imaging techniques including colour Doppler were used to identify the umbilical vein in the cord and its inlet to the abdomen. In two sheep a needle of gauge 19-20 was inserted after laparotomy either through the intact uterine wall or through a small uterotomy, and in all other sheep the umbilical vein was accessed percutaneously. 6-10 ml of 0.9% saline solution containing high or lower doses of recombinant virus were injected slowly into the vein. The appropriate site of injection was confirmed by tracing the injected fluid in the venous flow directed towards the fetus using ultrasound. The wounds were closed and the ewes permitted to recover. Ultrasound was used to monitor survival of the fetuses during the following days. All procedures on animals were conducted in accordance with UK Home Office regulations and the Guidance for the Operation of Animals (Scientific Procedures) Act (1986).
Dissection: Three ewes were killed after 3 days with an overdose of pentobarbitone and a post-mortem examination on ewes and fetuses was performed. Two sheep were killed prematurely, after a few hours and 1 day, respectively, because of intrauterine fetal death. Four sheep were allowed to give birth and were killed together with their lambs 1 day or later after birth.
The ewes were subjected to a limited post-mortem examination and samples of liver, lung and ovary were taken for histology. A full post-mortem examination was carried out on the dead fetal and neonatal sheep with widespread sampling of tissues from all organ systems including multiple tissue blocks from the liver and lungs.
Adenovirus
First generation (E1 and E3 regions deleted) adenovirus vectors AdRSV␤gal and AdTG9397 containing the ␤-galactosidase reporter gene 30 and the human factor IX gene (unpublished construct from the Transgene Laboratory, France), respectively, were prepared as previously described. 31, 32 Each vector was titered by plaque assays on 293 cells as previously stated and also tested for the absence of helper virus using HeLa and NIH3T3 cells as indicator cell lines. 31, 33 No passage of virus was detected after exposing 293 cells to HeLa supernatants after 2 weeks growth.
AdRSV␤gal contains an RSV promoter driving the expression of the ␤-galactosidase reporter gene. The factor IX gene on AdTG9397 is driven by the CMV promoter and contains the adenovirus tripartite leader sequence. Viruses were prepared freshly in physiological buffers before injection into sheep.
Histology
Tissue samples were fixed in 10% formalin overnight, transferred to 70% ethanol and processed into paraffin. Sections were stained with haematoxylin and eosin for morphological assessment. ␤-Galactosidase and factor IX were detected immuno-histochemically using a mouse monoclonal (Promega, Southampton, UK) and a rabbit polyclonal antibody (DAKO, High Wycombe, UK), respectively, followed by a standard avidin-biotin peroxidase method.
Determination of the plasma concentration of human factor IX Blood (nine volumes) was collected into tubes containing 0.109 m trisodium citrate (one volume). Plasma was obtained by centrifugation at 2500 g for 10 min and either analysed immediately or stored for less than 2 weeks at −20°C. In the latter case samples were thawed directly at 37°C for at least 15 min before testing. The concentration of the transgenic factor IX protein was determined using the Asserachrom IX enzyme-linked immunosorbent assay kit (Diagnostica Stago, Asnières-sur-Seine, France). The slight cross-reactivity between sheep and human factor IX was taken into account by increasing the assay's detection limit accordingly. Pooled normal human plasma assumed to contain factor IX in a concentration of 4 g/ml was used as assay standard.
Detection of anti-adenoviral antibodies and of antihuman factor IX antibodies Anti-adenoviral antibodies were detected by ELISA. 96-well plates were coated at 4°C overnight with 1 × 10 9 p.f.u. of adenovirus, followed by washing with phosphate-buffered saline and saturation with 3% bovine serum albumin for 60 min at 37°C. Serum samples diluted 50-, 500-or 5000-fold with reagent 4 (Asserachrom IX ELISA kit) were added to the wells and left standing for 90 min at room temperature. After washing six times with reagent 5 (Asserachrom IX ELISA kit) a horseradish peroxidase-conjugated rabbit anti-sheep antibody (DAKO) was applied (90 min at room temperature) followed by six washes with reagent 5. The horseradish peroxidase was then allowed to react with ophenylenediamine dihydrochloride/H 2 O 2 substrate solution. After 3 min the reaction was stopped by addition of 1 m HCl and the absorbancies were measured at 492 nm. This assay may detect sheep IgM as well as IgG (DAKO). A cross-reactive goat anti-adenovirus antibody (Skybio, Bedford, UK) was used as positive control.
The presence of anti-human factor IX antibodies was detected analogously on 96-well plates coated with human factor IX. A cross-reactive goat anti-human factor IX antibody (Skybio) was used as positive control.
Molecular analysis
Tissue samples were analysed for the presence of vector using the polymerase chain reaction (PCR). Primer sequences were designed to amplify DNA sequences from position 4018-4817 of the AdRSV␤gal virus from a range of sheep tissues. This region contains a part of the ␤-galactosidase reporter gene and adenovirus E1B sequences 3Ј to this region. Genomic DNA prepared from freshly frozen tissue samples using a Nucleon I Kit (Scotlab, Strathclyde, UK) was used for analysis. PCR conditions using a Hybaid Omnigene thermal cycler were as follows per 200 ng of DNA in a 100 l reaction tube: MgCl 2 (1.5 m), 2.5 U Taq polymerase (Promega), 25 nmols dNTPs, 55 pmols of forward (GTTCAACATCAGCCGCTACAG) and reverse primer (TATGTTTACCGCCACACTCGC) (Genosys Biotechnologies, Pampisford, UK) for first round PCR. After 35 cycles, 5 l of each sample were used for nested PCR applying the above conditions. Primer sequences were designed to amplify AdRSV␤gal virus DNA between positions 4271-4759 for further 35 cycles (forward primer GTCGCTACCATTACCAGTTGG and reverse primer TTATCGATACCGTCGACCTCG).
Reverse transcriptase PCR (RT-PCR) was used to determine expression of the ␤-galactosidase gene in infected tissues. RNA was purified using an RNA Isolator Kit (Genosys Biotechnologies) and treated with DNase (GibcoBRL, Life Technologies, Paisley, UK) for 15 min at 25°C before first strand cDNA synthesis using a FirstStrand cDNA synthesis kit (Amersham Pharmacia Biotech, Buckinghamshire, UK). All procedures were carried out according to the manufacturer's instructions.
Samples were then amplified applying the PCR conditions stated above using primer sequences designed to amplify the lacZ gene between positions 2919-3111 (forward primer GTTTACAGGGCGGCTTCG and reverse primer TGCTGCTGGTGTTTTGCTTCC).
